BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company advancing a next generation pipeline of novel small molecule therapeutics targeting RAS and PI3K malignancies. Initially formed as a subsidiary of BridgeBio, BridgeBio Oncology Therapeutics aims to improve outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors.

R3 Vascular is a privately-held medical device company that developed a novel technology platform for fully bioresorbable sirolimus coated vascular scaffolds that are designed to deliver the ‘stent-like’ support of a scaffold along with the anti-inflammatory result of sirolimus, but ‘disappearing’ over time as the vessel heals. R3 Vascular is headquartered in Mountain View, California.

Telix is a biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and associated medical devices.

BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. 

Relation is a biotechnology company discovering and developing transformational medicines, with experimental and computational systems at its core. The company’s Lab-in-the-Loop approach combines single cell multi-omics directly from patient tissue, functional assays and machine learning to understand the biological processes in human health and disease. The company is rapidly advancing programmes using insights from its technology and data, starting with bone-related diseases.

Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class biologics engineered to bring together the precision of targeted therapy and the power of tumor modulators. The company’s bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, potentially offering long-lasting efficacy.

Lunair^TM Medical is developing a novel neuromodulation treatment for sleep apnea that works with the body’s natural breathing mechanism to maintain airway stability and patency for a full night’s sleep.  The Lunair^TM System aims to work with patients who currently do not have effective therapy for their sleep apnea.  Sleep Naturally, Rest Easy.

Ray Therapeutics is developing novel optogenetics gene therapies for patients with blinding diseases. The company’s mission is to use optogenetics to restore vision, independent of genetic mutation for patients with inherited retinal diseases. Ray Therapeutics is based in San Francisco, CA.